Xenon Pharmaceuticals (XENE) Misses Q1 EPS by 2c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.23), $0.02 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $601 thousand versus the consensus estimate of $3.3 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Xenon Pharmaceuticals (XENE) PT Lowered to $60 at Needham
• Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program
• Barclays says AI trade is maturing, favors greater diversification